BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/24/2022 12:41:49 PM | Browse: 383 | Download: 739
 |
Received |
|
2022-01-05 18:04 |
|
Peer-Review Started |
|
2022-01-05 18:06 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-02-15 00:10 |
|
Revised |
|
2022-04-01 09:13 |
|
Second Decision |
|
2022-05-05 03:14 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-07 00:44 |
|
Articles in Press |
|
2022-05-07 00:44 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-03 00:07 |
|
Typeset the Manuscript |
|
2022-05-13 08:19 |
|
Publish the Manuscript Online |
|
2022-05-24 12:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Andrea Pretta, Dario Spanu, Stefano Mariani, Nicole Liscia, Pina Ziranu, Valeria Pusceddu, Marco Puzzoni, Elena Massa, Mario Scartozzi and Eleonora Lai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mario Scartozzi, MD, Chairman, Full Professor, Medical Oncology Unit, University Hospital and University of Cagliari, SS 554, bivio per Sestu, km 4,500, Monserrato 09042, Cagliari, Italy. marioscartozzi@gmail.com, Monserrato 09042, Cagliari, Italy. marioscartozzi@gmail.com |
| Key Words |
Metastatic pancreatic ductal adenocarcinoma; Palliative chemotherapy; Real-world data; Molecular selection; Biomarkers; Second-line treatment |
| Core Tip |
The present letter is intended to contribute to the collection of data on pancreatic ductal adenocarcinoma (PDAC) treatments in second-line settings through our experience with the promising data of efficacy and safety of a small group of study patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin. We also focused on highlighting the subgroups of PDAC patients who might benefit from target treatments, such as a small proportion of mutated BRCAs, and to identify comorbidities or characteristics that impact the prognosis of PDAC patients through our retrospective analysis that demonstrate a correlation between type II diabetes mellitus and improved overall survival. |
| Publish Date |
2022-05-24 12:41 |
| Citation |
Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E. How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world. World J Clin Oncol 2022; 13(5): 417-422 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i5/417.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i5.417 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
